Description

Product Features

Briganix (Brigatinib) indicate for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who progress on or are intolerant to crizotinib.

This indication approve under accelerating approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Dosage and Administration

90 mg orally once daily for the first 7 days; if tolerated, increase to 180 mg orally once daily. May be taken with or without food. Brigatinib use to treat different type of lung cancer (non-small cell lung cancer). It works by slowing or stopping the growth of cancer cells.

Side Effects

Nausea/vomiting, diarrhea, decreased appetite, abdominal pain, constipation, tiredness, dizziness, fever, headache, trouble sleeping, or joint pain may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Warnings and Precautions

• Administer BRIGANIX until disease progression or unacceptable toxicity
• If BRIGANIX  interrupt for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerate dose.
• BRIGANIX tablets should swallowed whole. Do not crush or chew tablets
• If a dose of BRIGANIX missed or vomiting occurs after taking a dose, do not administer an additional dose. Take next dose at the scheduled time
• Avoid grapefruit or grapefruit juice as it may increase plasma concentrations of BRIGANIX
• Any advice on the use of the drug is for reference only. Please consult with doctor for medical advice. All Names, logos, trademarks are property of their respective owners. Watermarks, QR code used for identification purposes only.

For more Oncology medicine, visit our SHOP